A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Healthy Adults
Latest Information Update: 23 Sep 2024
At a glance
- Drugs EDG-7500 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; First in man
- Sponsors Edgewise Therapeutics
Most Recent Events
- 19 Sep 2024 According to an Edgewise Therapeutics media release, members of the Edgewise management team will hold a live webcast on Thursday, September 19, 2024, at 8:30 am ET to discuss the top-line data from this study.
- 19 Sep 2024 Results presented in an Edgewise Therapeutics media release.
- 16 Jul 2024 Status changed from recruiting to completed.